Clinical Trial

A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study

Not Yet Recruiting

Record status

This record was last updated October 12, 2023 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.

Summary

Clinical studies, with a distinct emphasis on medullary thyroid cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications surpass conventional therapies, providing substantial evidence to endorse their broader adoption. The primary objective is to meticulously examine trial completion rates and voluntary withdrawals within this specific patient group. By actively participating in this observational study plays a critical role in pushing medical knowledge forward and advancing care for individuals suffering from the medullary thyroid cancer.

Trial Details

NCT Number	NCT06079723
Lead Sponsor	Power Life Sciences Inc.
Conditions	Medullary Thyroid Cancer
Enrollment	500 participants
Start Date	2024-11
Primary Completion	2025-11 (estimated)
Study Completion	2026-11 (estimated)
Updated on ClinicalTrials.gov	2023-10-12